Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease

Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.

Download Full-text

Mo1115 WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL DISEASE REVEAL TRANSCRIPTION FACTOR INVOLVEMENT

Gastroenterology ◽

10.1016/s0016-5085(20)32656-1 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-792-S-793

Author(s):

Jan Nowak ◽

Alex Adams ◽

Rahul Kalla ◽

Daniel Bergemalm ◽

Simen Vatn ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Transcription Factor ◽

Bowel Disease ◽

Whole Blood ◽

Expression Profiles ◽

Inflammatory Bowel

Download Full-text

The Emerging Role of Noncoding RNAs in Pediatric Inflammatory Bowel Disease

Inflammatory Bowel Diseases ◽

10.1093/ibd/izaa009 ◽

2020 ◽

Vol 26 (7) ◽

pp. 985-993 ◽

Cited By ~ 1

Author(s):

Petr Jabandziev ◽

Julia Bohosova ◽

Tereza Pinkasova ◽

Lumir Kunovsky ◽

Ondrej Slaby ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Expression Profiles ◽

Significant Proportion ◽

Noncoding Rnas ◽

Inflammatory Disorder ◽

Altered Expression ◽

Clinical Biomarkers ◽

Inflammatory Bowel ◽

Pediatric Ibd

Abstract Prevalence of inflammatory bowel disease (IBD), a chronic inflammatory disorder of the gut, has been on the rise in recent years—not only in the adult population but also especially in pediatric patients. Despite the absence of curative treatments, current therapeutic options are able to achieve long-term remission in a significant proportion of cases. To this end, however, there is a need for biomarkers enabling accurate diagnosis, prognosis, and prediction of response to therapies to facilitate a more individualized approach to pediatric IBD patients. In recent years, evidence has continued to evolve concerning noncoding RNAs (ncRNAs) and their roles as integral factors in key immune-related cellular pathways. Specific deregulation patterns of ncRNAs have been linked to pathogenesis of various diseases, including pediatric IBD. In this article, we provide an overview of current knowledge on ncRNAs, their altered expression profiles in pediatric IBD patients, and how these are emerging as potentially valuable clinical biomarkers as we enter an era of personalized medicine.

Download Full-text